HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
Purpose We examined the correlation between HER2 expression and pathologic complete response (pCR) to paclitaxel/FAC (T/FAC) preoperative chemotherapy in breast cancer. Patients and Methods Retrospective analysis of data including 534 patients treated with preoperative T/FAC was performed. Gene expr...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2008-03, Vol.108 (2), p.183-190 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 190 |
|---|---|
| container_issue | 2 |
| container_start_page | 183 |
| container_title | Breast cancer research and treatment |
| container_volume | 108 |
| creator | Andre, Fabrice Mazouni, Chafika Liedtke, Cornelia Kau, Shu-Wan Frye, Debby Green, Marjorie Gonzalez-Angulo, Ana M. Symmans, W. Fraser Hortobagyi, Gabriel N. Pusztai, Lajos |
| description | Purpose
We examined the correlation between HER2 expression and pathologic complete response (pCR) to paclitaxel/FAC (T/FAC) preoperative chemotherapy in breast cancer.
Patients and Methods
Retrospective analysis of data including 534 patients treated with preoperative T/FAC was performed. Gene expression results were available from two datasets of 132 and 286 patients, and were used to examine the co-expression of HER2 and topoisomerase II α (TOP2A) and microtubule associated protein tau (MAP-Tau).
Results
Of the 534 patients, 105 (20%) had HER2-overexpressing breast cancer. The pCR rates were 33% and 15% for patients with HER2+ and HER2- tumors (
P |
| doi_str_mv | 10.1007/s10549-007-9594-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_212472552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1442937201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-e18b0750e0e7ff787cf5caa29501b419e8fc933e8b0e46246d70a2ac36ae9b873</originalsourceid><addsrcrecordid>eNp1kEtLAzEUhYMotj5-gBsJgsuxN5lkkixLqQ8QBNGFqyGT3tgp7cyYTMX-e1Na7MrVPXC--zqEXDG4YwBqFBlIYbIkMyONyPQRGTKp8kxxpo7JEFihskJDMSBnMS4AwCgwp2TAlCi0EXpIPh6nr5ziTxcwxrptqG1mFL2vnXUb2nqajLbDYPv6G2ln3bLu7Q8uR_fjCXVzXLX9PLndhtYNrQLa2FNnG4fhgpx4u4x4ua_n5P1--jZ5zJ5fHp4m4-fMiUL2GTJdgZKAgMp7pZXz0lnLjQRWCWZQe2fyHBOFouCimCmw3Lq8sGgqrfJzcrOb24X2a42xLxftOjRpZckZF4pLyRPEdpALbYwBfdmFemXDpmRQbrMsd1mWW7nNstSp53o_eF2tcHbo2IeXgNs9YKOzSx_S33X84zhwUIKbxPEdF5PVfGI4XPj_9l-12IvR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212472552</pqid></control><display><type>article</type><title>HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Andre, Fabrice ; Mazouni, Chafika ; Liedtke, Cornelia ; Kau, Shu-Wan ; Frye, Debby ; Green, Marjorie ; Gonzalez-Angulo, Ana M. ; Symmans, W. Fraser ; Hortobagyi, Gabriel N. ; Pusztai, Lajos</creator><creatorcontrib>Andre, Fabrice ; Mazouni, Chafika ; Liedtke, Cornelia ; Kau, Shu-Wan ; Frye, Debby ; Green, Marjorie ; Gonzalez-Angulo, Ana M. ; Symmans, W. Fraser ; Hortobagyi, Gabriel N. ; Pusztai, Lajos</creatorcontrib><description>Purpose
We examined the correlation between HER2 expression and pathologic complete response (pCR) to paclitaxel/FAC (T/FAC) preoperative chemotherapy in breast cancer.
Patients and Methods
Retrospective analysis of data including 534 patients treated with preoperative T/FAC was performed. Gene expression results were available from two datasets of 132 and 286 patients, and were used to examine the co-expression of HER2 and topoisomerase II α (TOP2A) and microtubule associated protein tau (MAP-Tau).
Results
Of the 534 patients, 105 (20%) had HER2-overexpressing breast cancer. The pCR rates were 33% and 15% for patients with HER2+ and HER2- tumors (
P
< 0.001). The 5-year relapse-free survival rates were 94% and 70% in HER2+ tumors with and without pCR (
P
= 0.009). HER2 overexpression (odds ratio 2.3, 95%CI: 1.3–3.9,
P
= 0.004), estrogen receptor (ER) status, grade and weekly schedule of paclitaxel were each significantly and independently associated with pCR in multivariate analysis. When patients were stratified by ER status, the pCR rates were 50% for HER2+/ER−, 30% for HER2−/ER−, 19% for HER2+/ER+, and 6% for HER2−/ER+ tumors. HER2 overexpression was associated with lower expression of MAP-tau (
P
= 0.001 and
P
< 0.001) and higher expression of TOP2A mRNAs (
P
= 0.048 and
P
= 0.001) in patients with ER+ disease. ER− cancers had low MAP-tau expression regardless of HER-status.
Conclusion
HER2 overexpression is associated with higher rate of pCR to preoperative T/FAC chemotherapy regardless of ER status. HER2 overexpression also correlates with increased TOP2A and decreased MAP-tau expression in ER-positive cancers.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-007-9594-8</identifier><identifier>PMID: 17468948</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Antigens, Neoplasm - genetics ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Breast Neoplasms - surgery ; Cancer research ; Cancer therapies ; Chemotherapy ; Clinical outcomes ; Cyclophosphamide - administration & dosage ; Disease-Free Survival ; DNA Topoisomerases, Type II - genetics ; DNA-Binding Proteins - genetics ; Doxorubicin - administration & dosage ; Drug Administration Schedule ; Female ; Fluorouracil - administration & dosage ; Gene Amplification ; Gene expression ; Gene Expression Profiling - methods ; Gene Expression Regulation, Neoplastic ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Oligonucleotide Array Sequence Analysis ; Oncology ; Paclitaxel - administration & dosage ; Patient Selection ; Poly-ADP-Ribose Binding Proteins ; Preclinical Study ; Receptor, ErbB-2 - genetics ; Receptors, Estrogen - analysis ; Retrospective Studies ; RNA, Messenger - analysis ; tau Proteins - genetics ; Time Factors ; Treatment Outcome ; Tumors</subject><ispartof>Breast cancer research and treatment, 2008-03, Vol.108 (2), p.183-190</ispartof><rights>Springer Science+Business Media, LLC 2007</rights><rights>2008 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC. 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-e18b0750e0e7ff787cf5caa29501b419e8fc933e8b0e46246d70a2ac36ae9b873</citedby><cites>FETCH-LOGICAL-c465t-e18b0750e0e7ff787cf5caa29501b419e8fc933e8b0e46246d70a2ac36ae9b873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-007-9594-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-007-9594-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20207429$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17468948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Andre, Fabrice</creatorcontrib><creatorcontrib>Mazouni, Chafika</creatorcontrib><creatorcontrib>Liedtke, Cornelia</creatorcontrib><creatorcontrib>Kau, Shu-Wan</creatorcontrib><creatorcontrib>Frye, Debby</creatorcontrib><creatorcontrib>Green, Marjorie</creatorcontrib><creatorcontrib>Gonzalez-Angulo, Ana M.</creatorcontrib><creatorcontrib>Symmans, W. Fraser</creatorcontrib><creatorcontrib>Hortobagyi, Gabriel N.</creatorcontrib><creatorcontrib>Pusztai, Lajos</creatorcontrib><title>HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
We examined the correlation between HER2 expression and pathologic complete response (pCR) to paclitaxel/FAC (T/FAC) preoperative chemotherapy in breast cancer.
Patients and Methods
Retrospective analysis of data including 534 patients treated with preoperative T/FAC was performed. Gene expression results were available from two datasets of 132 and 286 patients, and were used to examine the co-expression of HER2 and topoisomerase II α (TOP2A) and microtubule associated protein tau (MAP-Tau).
Results
Of the 534 patients, 105 (20%) had HER2-overexpressing breast cancer. The pCR rates were 33% and 15% for patients with HER2+ and HER2- tumors (
P
< 0.001). The 5-year relapse-free survival rates were 94% and 70% in HER2+ tumors with and without pCR (
P
= 0.009). HER2 overexpression (odds ratio 2.3, 95%CI: 1.3–3.9,
P
= 0.004), estrogen receptor (ER) status, grade and weekly schedule of paclitaxel were each significantly and independently associated with pCR in multivariate analysis. When patients were stratified by ER status, the pCR rates were 50% for HER2+/ER−, 30% for HER2−/ER−, 19% for HER2+/ER+, and 6% for HER2−/ER+ tumors. HER2 overexpression was associated with lower expression of MAP-tau (
P
= 0.001 and
P
< 0.001) and higher expression of TOP2A mRNAs (
P
= 0.048 and
P
= 0.001) in patients with ER+ disease. ER− cancers had low MAP-tau expression regardless of HER-status.
Conclusion
HER2 overexpression is associated with higher rate of pCR to preoperative T/FAC chemotherapy regardless of ER status. HER2 overexpression also correlates with increased TOP2A and decreased MAP-tau expression in ER-positive cancers.</description><subject>Antigens, Neoplasm - genetics</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical outcomes</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>DNA Topoisomerases, Type II - genetics</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Doxorubicin - administration & dosage</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Gene Amplification</subject><subject>Gene expression</subject><subject>Gene Expression Profiling - methods</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Staging</subject><subject>Oligonucleotide Array Sequence Analysis</subject><subject>Oncology</subject><subject>Paclitaxel - administration & dosage</subject><subject>Patient Selection</subject><subject>Poly-ADP-Ribose Binding Proteins</subject><subject>Preclinical Study</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptors, Estrogen - analysis</subject><subject>Retrospective Studies</subject><subject>RNA, Messenger - analysis</subject><subject>tau Proteins - genetics</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kEtLAzEUhYMotj5-gBsJgsuxN5lkkixLqQ8QBNGFqyGT3tgp7cyYTMX-e1Na7MrVPXC--zqEXDG4YwBqFBlIYbIkMyONyPQRGTKp8kxxpo7JEFihskJDMSBnMS4AwCgwp2TAlCi0EXpIPh6nr5ziTxcwxrptqG1mFL2vnXUb2nqajLbDYPv6G2ln3bLu7Q8uR_fjCXVzXLX9PLndhtYNrQLa2FNnG4fhgpx4u4x4ua_n5P1--jZ5zJ5fHp4m4-fMiUL2GTJdgZKAgMp7pZXz0lnLjQRWCWZQe2fyHBOFouCimCmw3Lq8sGgqrfJzcrOb24X2a42xLxftOjRpZckZF4pLyRPEdpALbYwBfdmFemXDpmRQbrMsd1mWW7nNstSp53o_eF2tcHbo2IeXgNs9YKOzSx_S33X84zhwUIKbxPEdF5PVfGI4XPj_9l-12IvR</recordid><startdate>20080301</startdate><enddate>20080301</enddate><creator>Andre, Fabrice</creator><creator>Mazouni, Chafika</creator><creator>Liedtke, Cornelia</creator><creator>Kau, Shu-Wan</creator><creator>Frye, Debby</creator><creator>Green, Marjorie</creator><creator>Gonzalez-Angulo, Ana M.</creator><creator>Symmans, W. Fraser</creator><creator>Hortobagyi, Gabriel N.</creator><creator>Pusztai, Lajos</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20080301</creationdate><title>HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer</title><author>Andre, Fabrice ; Mazouni, Chafika ; Liedtke, Cornelia ; Kau, Shu-Wan ; Frye, Debby ; Green, Marjorie ; Gonzalez-Angulo, Ana M. ; Symmans, W. Fraser ; Hortobagyi, Gabriel N. ; Pusztai, Lajos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-e18b0750e0e7ff787cf5caa29501b419e8fc933e8b0e46246d70a2ac36ae9b873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antigens, Neoplasm - genetics</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical outcomes</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>DNA Topoisomerases, Type II - genetics</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Doxorubicin - administration & dosage</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Gene Amplification</topic><topic>Gene expression</topic><topic>Gene Expression Profiling - methods</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Staging</topic><topic>Oligonucleotide Array Sequence Analysis</topic><topic>Oncology</topic><topic>Paclitaxel - administration & dosage</topic><topic>Patient Selection</topic><topic>Poly-ADP-Ribose Binding Proteins</topic><topic>Preclinical Study</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptors, Estrogen - analysis</topic><topic>Retrospective Studies</topic><topic>RNA, Messenger - analysis</topic><topic>tau Proteins - genetics</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Andre, Fabrice</creatorcontrib><creatorcontrib>Mazouni, Chafika</creatorcontrib><creatorcontrib>Liedtke, Cornelia</creatorcontrib><creatorcontrib>Kau, Shu-Wan</creatorcontrib><creatorcontrib>Frye, Debby</creatorcontrib><creatorcontrib>Green, Marjorie</creatorcontrib><creatorcontrib>Gonzalez-Angulo, Ana M.</creatorcontrib><creatorcontrib>Symmans, W. Fraser</creatorcontrib><creatorcontrib>Hortobagyi, Gabriel N.</creatorcontrib><creatorcontrib>Pusztai, Lajos</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Andre, Fabrice</au><au>Mazouni, Chafika</au><au>Liedtke, Cornelia</au><au>Kau, Shu-Wan</au><au>Frye, Debby</au><au>Green, Marjorie</au><au>Gonzalez-Angulo, Ana M.</au><au>Symmans, W. Fraser</au><au>Hortobagyi, Gabriel N.</au><au>Pusztai, Lajos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2008-03-01</date><risdate>2008</risdate><volume>108</volume><issue>2</issue><spage>183</spage><epage>190</epage><pages>183-190</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>Purpose
We examined the correlation between HER2 expression and pathologic complete response (pCR) to paclitaxel/FAC (T/FAC) preoperative chemotherapy in breast cancer.
Patients and Methods
Retrospective analysis of data including 534 patients treated with preoperative T/FAC was performed. Gene expression results were available from two datasets of 132 and 286 patients, and were used to examine the co-expression of HER2 and topoisomerase II α (TOP2A) and microtubule associated protein tau (MAP-Tau).
Results
Of the 534 patients, 105 (20%) had HER2-overexpressing breast cancer. The pCR rates were 33% and 15% for patients with HER2+ and HER2- tumors (
P
< 0.001). The 5-year relapse-free survival rates were 94% and 70% in HER2+ tumors with and without pCR (
P
= 0.009). HER2 overexpression (odds ratio 2.3, 95%CI: 1.3–3.9,
P
= 0.004), estrogen receptor (ER) status, grade and weekly schedule of paclitaxel were each significantly and independently associated with pCR in multivariate analysis. When patients were stratified by ER status, the pCR rates were 50% for HER2+/ER−, 30% for HER2−/ER−, 19% for HER2+/ER+, and 6% for HER2−/ER+ tumors. HER2 overexpression was associated with lower expression of MAP-tau (
P
= 0.001 and
P
< 0.001) and higher expression of TOP2A mRNAs (
P
= 0.048 and
P
= 0.001) in patients with ER+ disease. ER− cancers had low MAP-tau expression regardless of HER-status.
Conclusion
HER2 overexpression is associated with higher rate of pCR to preoperative T/FAC chemotherapy regardless of ER status. HER2 overexpression also correlates with increased TOP2A and decreased MAP-tau expression in ER-positive cancers.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>17468948</pmid><doi>10.1007/s10549-007-9594-8</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2008-03, Vol.108 (2), p.183-190 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_journals_212472552 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antigens, Neoplasm - genetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Breast Neoplasms - surgery Cancer research Cancer therapies Chemotherapy Clinical outcomes Cyclophosphamide - administration & dosage Disease-Free Survival DNA Topoisomerases, Type II - genetics DNA-Binding Proteins - genetics Doxorubicin - administration & dosage Drug Administration Schedule Female Fluorouracil - administration & dosage Gene Amplification Gene expression Gene Expression Profiling - methods Gene Expression Regulation, Neoplastic Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Medicine Medicine & Public Health Middle Aged Neoadjuvant Therapy Neoplasm Staging Oligonucleotide Array Sequence Analysis Oncology Paclitaxel - administration & dosage Patient Selection Poly-ADP-Ribose Binding Proteins Preclinical Study Receptor, ErbB-2 - genetics Receptors, Estrogen - analysis Retrospective Studies RNA, Messenger - analysis tau Proteins - genetics Time Factors Treatment Outcome Tumors |
| title | HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T07%3A53%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HER2%20expression%20and%20efficacy%20of%20preoperative%20paclitaxel/FAC%20chemotherapy%20in%20breast%20cancer&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Andre,%20Fabrice&rft.date=2008-03-01&rft.volume=108&rft.issue=2&rft.spage=183&rft.epage=190&rft.pages=183-190&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-007-9594-8&rft_dat=%3Cproquest_cross%3E1442937201%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212472552&rft_id=info:pmid/17468948&rfr_iscdi=true |